Phase I/II, Open-Label Trial of Three Monoclonal Antibodies

Completed · Phase 1/Phase 2

Conditions studied: HIV Infections

In brief

Monoclonal antibody infusions will prevent rebound of viremia in well-suppressed HAART-treated individuals who began therapy during acute and early HIV-1 infection.

Key facts

Study ID

NCT00219986

Run by

Rockefeller University

People needed

12

Starts

2003-10-01

Expected to finish

2005-09-01

Last updated by the study team

2007-07-18

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may not qualify if…

• More than 1 detectable HIV-1 RNA value (>50 copies/mL) within 6 months of screening visit
• Pregnancy and breast-feeding.
• Active drug or alcohol use or dependence that, in the opinion of the investigator, would interfere with adherence to study requirements.
• Serious illness (requiring systemic treatment and/or hospitalization) until subject either completes therapy or is clinically stable on therapy, in the opinion of the investigator, for at least 30 days prior to study entry.

Where it is running

• Rockefeller University Hospital — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.